Aclasta (zoledronic acid) - Important Safety Information from Novartis as approved by the Irish Medicines Board
15 March 2010
Important Safety Information communication from Novartis on reports of renal impairment and renal failure with Aclasta (zoledronic acid, 5 mg solution for infusion).
Important Safety Information - Aclasta (zoledronic acid)